Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Scar Management Hydrogel Nov 4, 2014
Oculus Innovative Sciences Receives European CE Mark for New Microcyn(R)-Based Atopic Dermatitis Hydrogel Oct 30, 2014
Oculus Innovative Sciences Announces Fiscal Second Quarter 2015 Financial Results and Conference Call Oct 30, 2014
Oculus Innovative Sciences Strengthens Intellectual Property Portfolio With Allowance of Four New Patents for Microcyn(R) Technology Sep 16, 2014
Oculus Innovative Sciences Introduces Microcyn(R)-Based Over-the-Counter Advanced Scar Management Hydrogel in United States Sep 10, 2014
Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015 Aug 7, 2014
Oculus Innovative Sciences Announces Fiscal First Quarter 2015 Financial Results and Conference Call Jul 24, 2014
Oculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen IPO Transaction Jun 12, 2014
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2014 Financial Results and Conference Call May 29, 2014
Oculus Innovative Sciences' Partner, More Pharma, Launches Microcyn(R)-Based Oral and Throat Infection Treatment Product in Mexico Apr 22, 2014
